Dysphonia as an unusual toxic event of oxaliplatin-based chemotherapy

Journal of Chemotherapy

Volumn 16, Issue 6, 2004, Pages 595-598

  Berretta, M ^a   Taibi, R ^b   Bearz, A ^a   La Mura, N ^c   Berretta, S ^b   Tirelli, U ^a   Frustaci, Sergio ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c Centro di Riferimento Oncologico ^*

Author keywords

Chemotherapy toxicity; Colorectal cancer; Dysphonia; Oxaliplatin; Side effects

Indexed keywords

ANTINEOPLASTIC AGENT; BICARBONATE; CALCIUM; CAPECITABINE; CARBAMAZEPINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; FOLINIC ACID; GABAPENTIN; GLUTATHIONE; IRINOTECAN; OXALIC ACID; OXALIPLATIN; PLATINUM DERIVATIVE; RALTITREXED; SODIUM CHANNEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INFUSION; DRUG SAFETY; DRUG UTILIZATION; DYSESTHESIA; DYSPHONIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LARYNX DISORDER; LARYNX SPASM; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MYOKYMIA; MYOTONIA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; OTOTOXICITY; PARESTHESIA; PATIENT EDUCATION; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; RESPIRATORY DISTRESS; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SYMPTOM;

EID: 12544256871     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2004.16.6.595     Document Type: Article

References (19)

1. Wilson RH, Lehky T, et al. Acute oxaliplatin-induced peripheral nerve hyperxcitability. J Clinic Oncol 2002; 20: 1767-1774.
2. Tashiro T, Kawada Y, Sakurai Y, Kidani Y. Antitumor activity of a new platinum complex, oxalato (trans-1-1,2-diaminocyclohexane)platinum (11): new experimental data. Biomed Pharmacother 1989; 43: 251-60.
3. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52: 1855-65.
4. Becouarn Y, Rougier P. Clinical efficacy of oxaliplatin monotherapy: Phase II trials in advanced colorectal cancer. Semin Oncol 1998; 25: 23-31.
5. Giacchetti S, Zidani R, Perpoint B, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
6. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
7. Bleiberg H, de Gramont A. Oxaliplatin plus 5-fluouracil: Clinical experience in patients with advanced colorectal cancer. Semin Oncol 1998; 25: 32-39.
8. de Gramont A, Vignoud J, Tournigand C et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer. 1997; 33: 214-9.
9. Misset JL. Oxaliplatin in practice. Br J Cancer 1998; 77: 4-7.
10. Mollman JE. Cisplatin neurotoxicity. N Engl J Med 1990; 322: 126-127.
11. Sorbye H, Glimelius B, Berglund A et al. Multicenter phase II study of Nordic fluorouracile and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004; 1,22 (1): 31-38.
12. Norum J. Oxaliplatin in colorectal cancer patients living in an arctic or subarctic area: significant cold-triggered dysesthesias and laryngeal reactions. J Chemother 2000; 12: 525-529.
13. Extra JM, Espie M, Calvo F et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25: 299-303.
14. Brienza S, Vignoud J, Itzhaki M, et al. Oxaliplatin (L-OHP): Global safetyin 682 patients. Proc Am Soc Clin Oncol 14:209, 1995 (abstr 513).
15. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003; 30: suppl 15 5-13.
16. Taieb S, Trillet-Lenoir V, Rambaud L, et al. Lhermitte sign and urinary retention: Atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer 2002; 94: 2434-2440.
17. Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Onc 2002; 29, suppl 15: 11-20.
18. Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo controlled trial. J Clin Oncol 2002; 15,20 (16): 3478-3483.
19. Levi F, Misset JL, Brienza S et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992; 69: 893-900.